eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

6/2021
vol. 13
 
Share:
Share:
more
 
 
abstract:
Case report

Orbital mold brachytherapy for recurrent orbital mesenchymal chondrosarcoma: a case report

Eugene Yap
1
,
Stellar Cabrera
1
,
Maureen Bojador
1
,
Teresa Sy Ortin
1
,
Warren Bacorro
1

1.
University of Santo Tomas Hospital, Benavides Cancer Institute, Manila, Philippines; University of Santo Tomas Faculty of Medicine and Surgery, Manila, Philippines
J Contemp Brachytherapy 2021; 13, 6: 694–700
Online publish date: 2021/12/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The aim of this case report is to present a case of orbital mesenchymal chondrosarcoma sarcoma with multiple recurrences, and to report technical details of a contemporary approach for orbital brachytherapy that can be used in low-resource settings.

Material and methods
A 46-year-old female diagnosed with recurrent orbital mesenchymal chondrosarcoma of the left orbit presented with her third local recurrence. The patient proceeded with conservative surgery with planned adjuvant high-dose-rate brachytherapy 2 weeks post-surgery. Brachytherapy mold applicator was fabricated using thermoplastic mask, ProGuide catheter needles, catheter fixation buttons, and a strip of gauze. Ideal catheter placement was done with CT simulation planning.

Results
High-risk clinical target volume (HR-CTV) corresponded to gross tumor residual, and intermediate-risk clinical target volume (IR-CTV) corresponded to the whole orbit. Flexitron iridium-192 high-dose-rate (HDR) brachytherapy plan was generated using Oncentra brachytherapy planning system. The treatment plan had HR-CTV total dose of 55.6 Gy and equivalent dose in 2 Gray fractions (EQD2) of 96 Gy. IR-CTV total dose was 45.5 Gy and EQD2 of 70 Gy. The plan was evaluated using dose-volume histogram and dosimetric parameters, which showed adequate irradiation of tumor volume and at-risk areas. The patient underwent orbital brachytherapy without any adverse events, except for mild skin erythema. One-year post-treatment showed no local recurrence and no soft tissue necrosis or swelling.

Conclusions
In the previously irradiated orbital sarcoma patient, adjuvant brachytherapy is an effective and safe modality for the delivery of sufficient radiation dose to the target, as presented in the current case report. The materials used in the brachytherapy applicator are easily available in majority of radiation therapy centers and can be manufactured even in low-resource settings.

keywords:

orbit, brachytherapy, high-dose-rate, sarcoma, case report

 
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.